Sanofim
Sanofi’s Sarclisa accepted for FDA priority review
May 29, 2024Medical Communications FDA, Oncology, Sanofim, Sarclisa, multiple myeloma, priority review
Sanofi has announced that the US Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for …
Latest content
October 28, 2026
Acumentis CEO Herspiegel steps down as Burden assumes role
October 27, 2026
